Cover Image

FDA checkup : drug development and manufacturing challenges : hearing before the Subcommittee on Energy Policy, Health Care and Entitlements of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Thirteenth Congress, first session, December 12, 2013.

Bibliographic Details
Corporate Author:	United States. Congress. House. Committee on Oversight and Government Reform. Subcommittee on Energy Policy, Health Care, and Entitlements (Author)
Format:	Government Document eBook
Language:	English
Published:	Washington : U.S. Government Printing Office, 2014.
Subjects:	Drug development > Government policy > United States. Drug approval > United States. Drugs > United States > Testing > Government policy. Legislative hearings.
Online Access:	https://purl.fdlp.gov/GPO/gpo49004 http://purl.fdlp.gov/GPO/gpo49004

Similar Items

Reviewing FDA's implementation of FDASIA : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, first session, November 15, 2013.
Published: (2014)

Guidance for FDA staff and industry : marketed unapproved drugs, compliance policy guide.
Published: (2006)

Guidance for industry and FDA staff : how to write a request for designation (RFD).
Published: (2005)

FDA Checkup : Drug Development and Manufacturing Challenges.
Published: (2013)

FDA user fees 2012 : issues related to accelerated approval, medical gas, antibiotic development, and downstream pharmaceutical supply chain : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, March 8, 2012.
Published: (2013)

Guidance for industry : ANDAs, impurities in drug products.
Published: (2005)

Guidance for industry : ANDAs, impurities in drug substances.
Published: (2009)

PDUFA V : medical innovation, jobs, and patients : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, first session, July 7, 2011.
Published: (2012)

Guidance for industry and FDA staff : application user fees for combination products.
Published: (2005)

Animal drug user fee agreements : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, first session, on examining animal drug user fee agreements, focusing on advancing animal health for the public health, February 27, 2013.
Published: (2014)

Guidance for industry : M4, organization of the CTD.
Published: (2001)

The administration's FDA reforms and reduced biopharmaceutical drug prices /
Published: (2018)

Improving predictability and transparency in DEA and FDA regulation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 7, 2014.
Published: (2015)

Guidance for industry : formal meetings between the FDA and sponsors or applicants.
Published: (2009)

Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012.
Published: (2013)

Guidance for industry : revising and ANDA labeling following revision of the RLD labeling.
Published: (2000)

Guidelines for submitting samples and analytical data for methods validation.
Published: (1987)

FDA's drug review process and the package label : strategies for writing successful FDA submissions /
by: Brody, Tom
Published: (2017)

Guidance for industry and FDA staff : submission and resolution of formal disputes regarding the timeliness of premarket review of a combination product.
Published: (2004)

Developments in the prescription drug market : oversight : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, February 4, 2016.
Published: (2017)

Drug manufacturing : FDA should fully assess its efforts to encourage innovation : report to congressional committees /
Published: (2023)

Guidance for industry : alternate source of the active pharmaceutical ingredient in pending ANDAs.
Published: (2000)

FDA user fees 2012 : how innovation helps patients and jobs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, April 18, 2012.
Published: (2013)

Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996.
Published: (1998)

CDER ... report to the nation : improving public health through human drugs /
Published: (1998)

Food and Drug Amendments of 2022 : report of the Committee on Energy and Commerce (to accompany H.R. 7667).
Published: (2022)

Guidance for industry : INDs for phase 2 and phase 3 studies, chemistry, manufacturing, and controls information.
Published: (2003)

Center for Drug Evaluation and Research update.

Preparing for FDA pre-approval inspections /
Published: (1999)

Guidance for FDA reviews and sponsors : content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs).
Published: (2008)

Staff report on Sanofi's strategic use of third parties to influence the FDA /
Published: (2011)

Challenges for the FDA : the future of drug safety : workshop summary /
Published: (2007)

Guidance for industry : format and content for the CMC section of an annual report.
Published: (1994)

Guidance for industry : M4Q, the CTD, quality.
Published: (2001)

The need for FDA regulatory reform to protect the health and safety of Americans : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, June 9, 1995.
Published: (1996)

Guidance for industry : M4S, the CTD, safety appendices.
Published: (2001)

Guidance for industry : M4S, the CTD, safety.
Published: (2001)

Reviewer guidance : conducting a clinical safety review of a new product application and preparing a report on the review.
Published: (2005)

Guidebook for drug regulatory submissions /
by: Weinberg, Sandy, 1950-
Published: (2009)